TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial
TRPC6抑制剂(BI 764198)降低COVID-19引起ARDS的风险和严重程度:一项II期随机对照试验
期刊:Thorax
影响因子:7.7
doi:10.1136/thorax-2022-219668
Ware, Lorraine B; Soleymanlou, Nima; McAuley, Danny Francis; Estrada, Vicente; Diaz, George A; Lacamera, Peter; Kaste, Renee; Choi, Wansuk; Gupta, Abhya; Welte, Tobias